c19early.org COVID-19 treatment researchCOVID-19 treatments

A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Kallend et al., NCT04676867, NCT04676867, May 2021
Early treatmentDouble-blind RCT · NCT04676867 · 227 patients · Canada
Dalcetrapib for COVID-19
Kallend et al. NCT04676867 · May 2021
Outcome
Improvement
Relative Risk · 95% CI
Mortality
-134%2.34 · 0.10 to >9
Ventilation
-134%2.34 · 0.10 to >9
Oxygen therapy
-139%2.39 · 0.30 to >9
Hospitalization
-37%1.37 · 0.30–6.24
00.511.52+
← Dalcetrapib
reduces riskDalcetrapib
increases risk →
Trial underpowered to detect differences
RCT 227 COVID-19 outpatients with symptom onset within 5 days, showing no signficiant benefits with dalcetrapib treatment.
Important missing comments or errors? Let us know.
OutcomeImprovementEffect · pTreatmentControl
risk of death 134.2% higher · RR 2.34 · p = 1.00 134.2% higherRR 2.34p = 1.00 1 of 155 (0.6%) 0 of 53 (0.0%) treatment 1 of 155 (0.6%), control 0 of 53 (0.0%)continuity correction due to zero events
risk of mechanical ventilation 134.2% higher · RR 2.34 · p = 1.00 134.2% higherRR 2.34p = 1.00 1 of 155 (0.6%) 0 of 53 (0.0%) treatment 1 of 155 (0.6%), control 0 of 53 (0.0%)continuity correction due to zero events
risk of oxygen therapy 139.4% higher · RR 2.39 · p = 0.68 139.4% higherRR 2.39p = 0.68 7 of 155 (4.5%) 1 of 53 (1.9%) treatment 7 of 155 (4.5%), control 1 of 53 (1.9%)
risk of hospitalization 36.8% higher · RR 1.37 · p = 1.00 36.8% higherRR 1.37p = 1.00 8 of 155 (5.2%) 2 of 53 (3.8%) treatment 8 of 155 (5.2%), control 2 of 53 (3.8%)

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Kallend et al., 17 May 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, preprint, 1 author, trial NCT04676867 (history). Contact: dkallend@dalcorpharma.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Canada Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Canada favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Canada Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Canada favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%